The US Food and Drug Administration recommends including ALT as an efficacy endpoint during the development of novel therapies for hepatitis B infection, highlighting the important role of this aminotransferase in monitoring liver outcomes [28]. This evidence concerns the gene GPT and hepatitis B virus infection.